Observational studyHeart (British Cardiac Society)2017
Ferumoxytol-enhanced magnetic resonance imaging assessing inflammation after myocardial infarction.
Observational study in Heart (British Cardiac Society), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02319278 (DEtection of Cellular Inflammation With FERumoxytol in the HEART), which is not on this map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
DEtection of Cellular Inflammation With FERumoxytol in the HEART
Who cites it
30 citing papers in PubMed, 63 citations in OpenAlex.
- Myocardial and Systemic Inflammation in Acute Stress-Induced (Takotsubo) Cardiomyopathy.Circulation · 2019 · on this mapTrial
- Effect of clinically relevant iron oxide nanoparticles on macrophage polarization, tumor growth and tumor microenvironment modulation.Journal of controlled release : official journal of the Controlled Release Society · 2026Article
- Molecular contrast agents for post-infarct cardiac remodelling: a contemporary review.European heart journal. Imaging methods and practice · 2026Review
- Mapping the immune environment: spatiotemporal dynamics in cardiovascular events.Frontiers in immunology · 2026Review
- Navigating the 2024 AHA guidelines for Kawasaki disease: practical insights for clinicians.World journal of pediatrics : WJP · 2025Article
- Ferumoxytol-enhanced cardiovascular magnetic resonance imaging: applications and technical advances.Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance · 2025Review
- Unveiling the next generation of MRI contrast agents: current insights and perspectives on ferumoxytol-enhanced MRI.National science review · 2024Review
- Accumulation of Iron Oxide-Based Contrast Agents in Rabbit Atherosclerotic Plaques in Relation to Plaque Age and Vulnerability Features.International journal of nanomedicine · 2024Article
- Exploring the causal relationship between immune cell and all-cause heart failure: a Mendelian randomization study.Frontiers in cardiovascular medicine · 2024Article
- Fractional myocardial blood volume by ferumoxytol-enhanced MRI: Estimation of ischemic burden.Magnetic resonance in medicine · 2023Article
- Magnetic resonance imaging contrast-enhancement with superparamagnetic iron oxide nanoparticles amplifies macrophage foam cell apoptosis in human and murine atherosclerosis.Cardiovascular research · 2023Article
- Applications of AI in multi-modal imaging for cardiovascular disease.Frontiers in radiology · 2023Review
- A primer onFrontiers in medicine · 2023Review
- Imaging Methods: Magnetic Resonance Imaging.Circulation. Cardiovascular imaging · 2023Review
- Myocardial inflammation and energetics by cardiac MRI: a review of emerging techniques.BMC medical imaging · 2021Review
- Iron Oxide Nanoparticles as Theranostic Agents in Cancer Immunotherapy.Nanomaterials (Basel, Switzerland) · 2021Review
- Ferumoxytol-enhanced magnetic resonance T1 reactivity for depiction of myocardial hypoperfusion.NMR in biomedicine · 2021Article
- Physiological and Pathological Factors Affecting Drug Delivery to the Brain by Nanoparticles.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021Review
- Estimation of fractional myocardial blood volume and water exchange using ferumoxytol-enhanced magnetic resonance imaging.Journal of magnetic resonance imaging : JMRI · 2021Article
- Disentangle, Align and Fuse for Multimodal and Semi-Supervised Image Segmentation.IEEE transactions on medical imaging · 2021Article
Corrections and comments
- Commented on by
Authors and funding
14 authors at 3 institutions in 1 country.
Funding
Abstract
objectivesMacrophages play a central role in the cellular inflammatory response to myocardial infarction (MI) and predict subsequent clinical outcomes. We aimed to assess temporal changes in cellular inflammation and tissue oedema in patients with acute MI using ultrasmallsuperparamagnetic particles of iron oxide (USPIO)-enhanced MRI.
methodsThirty-one patients were recruited following acute MI and followed up for 3 months with repeated T2 and USPIO-enhanced T2*-mapping MRI. Regions of interest were categorised into infarct, peri-infarct and remote myocardial zones, and compared with control tissues.
resultsFollowing a single dose, USPIO enhancement was detected in the myocardium until 24 hours (p<0.0001). Histology confirmed colocalisation of iron and macrophages within the infarcted, but not the non-infarcted, myocardium. Following repeated doses, USPIO uptake in the infarct zone peaked at days 2-3, and greater USPIO uptake was detected in the infarct zone compared with remote myocardium until days 10-16 (p<0.05). In contrast, T2-defined myocardial oedema peaked at days 3-9 and remained increased in the infarct zone throughout the 3-month follow-up period (p<0.01).
conclusionMyocardial macrophage activity can be detected using USPIO-enhanced MRI in the first 2 weeks following acute MI. This observed pattern of cellular inflammation is distinct, and provides complementary information to the more prolonged myocardial oedema detectable using T2 mapping. This imaging technique holds promise as a non-invasive method of assessing and monitoring myocardial cellular inflammation with potential application to diagnosis, risk stratification and assessment of novel anti-inflammatory therapeutic interventions. TRIAL REGISTRATION NUMBER: Trial registration number: 14663. Registered on UK Clinical Research Network (http://public.ukcrn.org.uk) and also ClinicalTrials.gov (https://clinicaltrials.gov/ct2/show/NCT02319278?term=DECIFER&rank=2).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.